InterVenn Biosciences vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
InterVenn Biosciences pioneered clinical glycoproteomics with AI-powered liquid biopsy diagnostics for cancer; raised $251M total, received AMA PLA code for non-invasive ovarian cancer test in July 2025.
About
InterVenn Biosciences is a clinical-stage diagnostics company that has pioneered the field of glycoproteomics — the study of proteins modified with sugar molecules (glycans) — combined with artificial intelligence to develop next-generation liquid biopsy tests for cancer detection and treatment monitoring. The company's VOCAL test provides a non-invasive diagnostic for ovarian cancer using a blood draw, and its GlycoKnowPR platform delivers glycoproteomic immunotherapy response assays to help oncologists predict how patients will respond to treatment before administering therapy.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
InterVenn Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.